MX2012002217A - Compuestos heterociclicos como inhibidores de cinasa janus. - Google Patents
Compuestos heterociclicos como inhibidores de cinasa janus.Info
- Publication number
- MX2012002217A MX2012002217A MX2012002217A MX2012002217A MX2012002217A MX 2012002217 A MX2012002217 A MX 2012002217A MX 2012002217 A MX2012002217 A MX 2012002217A MX 2012002217 A MX2012002217 A MX 2012002217A MX 2012002217 A MX2012002217 A MX 2012002217A
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- compounds
- kinase inhibitors
- heterocyclic compounds
- janus kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
La invención proporciona compuestos de la fórmula (I): (ver fórmula (I)) o una sal de los mismos como se describe en la presente. La invención también proporciona composiciones farmacéuticas que comprenden el compuesto de la fórmula (I), procedimientos para preparar los compuestos de la fórmula (I), intermediarios útiles para preparar compuestos de la fórmula (I) y métodos terapéuticos para suprimir una respuesta inmune o tratar cáncer o una malignidad hematológica usando los compuestos de la fórmula (I).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23754609P | 2009-08-27 | 2009-08-27 | |
US31358310P | 2010-03-12 | 2010-03-12 | |
PCT/US2010/046999 WO2011031554A2 (en) | 2009-08-27 | 2010-08-27 | Heterocyclic compounds as janus kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012002217A true MX2012002217A (es) | 2012-04-10 |
Family
ID=43558315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012002217A MX2012002217A (es) | 2009-08-27 | 2010-08-27 | Compuestos heterociclicos como inhibidores de cinasa janus. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20120149662A1 (es) |
EP (1) | EP2470537A2 (es) |
JP (1) | JP2013503191A (es) |
KR (1) | KR20120060867A (es) |
CN (1) | CN102574863A (es) |
AR (1) | AR077990A1 (es) |
AU (1) | AU2010292487A1 (es) |
BR (1) | BR112012008073A2 (es) |
CA (1) | CA2770712A1 (es) |
IL (1) | IL218271A0 (es) |
MX (1) | MX2012002217A (es) |
RU (1) | RU2012111215A (es) |
TW (1) | TW201111385A (es) |
WO (1) | WO2011031554A2 (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2474545T (lt) | 2005-12-13 | 2017-02-27 | Incyte Holdings Corporation | Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai |
LT3070090T (lt) | 2007-06-13 | 2019-06-25 | Incyte Holdings Corporation | Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas |
CA2732628A1 (en) * | 2008-08-01 | 2010-02-04 | Biocryst Pharmaceuticals, Inc. | Therapeutic agents |
JP5775070B2 (ja) | 2009-05-22 | 2015-09-09 | インサイト・コーポレイションIncyte Corporation | ヤヌスキナーゼ阻害剤としてのピラゾール−4−イル−ピロロ[2,3−d]ピリミジンおよびピロール−3−イル−ピロロ[2,3−d]ピリミジンのN−(ヘテロ)アリール−ピロリジン誘導体 |
MY161416A (en) | 2009-05-22 | 2017-04-14 | Incyte Holdings Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1h-pyrazol-1-yl]octane-or heptane-nitrile as jak inhibitors |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
AR081315A1 (es) | 2010-03-10 | 2012-08-08 | Incyte Corp | Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t |
ME02445B (me) | 2010-05-21 | 2016-09-20 | Incyte Holdings Corp | Topikalna formulacija za inhibiciju jak-a |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
AR083933A1 (es) | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
WO2012106448A1 (en) * | 2011-02-02 | 2012-08-09 | Biocryst Pharmaceuticals, Inc. | Heterocyclic compounds as janus kinase inhibitors |
PE20140832A1 (es) | 2011-06-20 | 2014-07-14 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
US8962608B2 (en) * | 2011-09-22 | 2015-02-24 | Merck Sharp & Dohme Corp. | Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
UA111687C2 (uk) | 2012-11-08 | 2016-05-25 | Пфайзер Інк. | Гетероароматичні сполуки як ліганди допаміну d1 |
CA3178452A1 (en) | 2012-11-15 | 2014-05-22 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
LT3489239T (lt) | 2013-03-06 | 2022-03-10 | Incyte Holdings Corporation | Jak inhibitoriaus gamybos būdai ir tarpiniai junginiai |
WO2014146249A1 (en) * | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors |
MY195091A (en) | 2013-08-07 | 2023-01-10 | Incyte Corp | Sustained Release Dosage Forms for a JAK1 Inhibitor |
UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
CN103601749B (zh) * | 2013-11-26 | 2016-04-27 | 大连联化化学有限公司 | 一种1-烷基吡唑-4-硼酸频哪醇酯的合成方法 |
EP3083618B1 (en) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
CN104926816A (zh) * | 2014-03-19 | 2015-09-23 | 江苏先声药物研究有限公司 | 一种托法替布类似物及其制备方法与应用 |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
CN105218548A (zh) * | 2014-06-09 | 2016-01-06 | 上海海和药物研究开发有限公司 | 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途 |
CN104860872A (zh) * | 2015-03-27 | 2015-08-26 | 天津药物研究院有限公司 | 一种双-(3r,4r)-1-苄基-n,4-二甲基哌啶-3-胺l-二对甲基苯甲酰酒石酸盐的合成方法 |
MX2017013797A (es) * | 2015-05-29 | 2018-03-21 | Wuxi Fortune Pharmaceutical Co Ltd | Inhibidor de janus quinasa. |
KR101730481B1 (ko) | 2015-06-01 | 2017-04-26 | 엘케이테크넷(주) | 지하 매설물 경로 탐지 장치 및 지하 매설물의 위치정보를 제공하기 위한 서버 |
HU230805B1 (hu) * | 2015-12-23 | 2018-06-28 | Egis Gyógyszergyár Zrt | Eljárás és köztitermék baricitinib előállítására |
US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
UA126231C2 (uk) | 2016-06-16 | 2022-09-07 | Деналі Терапьютікс Інк. | Піримідин-2-іламіно-1н-піразоли як інгібітори lrrk2 для застосування при лікуванні нейродегенеративних захворювань |
US20200157081A1 (en) * | 2017-05-24 | 2020-05-21 | Denali Therapeutics Inc. | Compounds, compositions and methods |
MY200629A (en) | 2017-08-01 | 2024-01-06 | Theravance Biopharma R&D Ip Llc | Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
WO2019152374A1 (en) | 2018-01-30 | 2019-08-08 | Incyte Corporation | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
MX2020010322A (es) | 2018-03-30 | 2022-11-30 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
JP7083203B2 (ja) * | 2018-06-06 | 2022-06-10 | ジェングル セラピューティクス,インコーポレイテッド | ピラゾロピリミジン誘導体、その用途並びに医薬組成物 |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
EP3914348A1 (en) | 2019-01-23 | 2021-12-01 | Theravance Biopharma R&D IP, LLC | Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors |
WO2020161209A1 (en) | 2019-02-06 | 2020-08-13 | Syngenta Crop Protection Ag | Herbicidal fused pyridazine compounds |
WO2020161208A1 (en) | 2019-02-06 | 2020-08-13 | Syngenta Crop Protection Ag | Herbicidal fused pyridazine compounds |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
CN115028638A (zh) * | 2022-06-09 | 2022-09-09 | 安徽大学 | 一种鲁索替尼中间体的制备方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
US5041556A (en) | 1990-12-11 | 1991-08-20 | American Cyanamid Company | Process for the preparation of insecticidal, acaricidal and molluscicidal 2-halopyrrole-3-carbonitrile compounds |
US5478830A (en) * | 1992-05-29 | 1995-12-26 | The Du Pont Merck Pharmaceutical Company | Fused-ring heterocycles for the treatment of atherosclerosis |
TW336932B (en) | 1992-12-17 | 1998-07-21 | Pfizer | Amino-substituted pyrazoles |
JP3138117B2 (ja) | 1993-06-11 | 2001-02-26 | 株式会社トクヤマ | 新規化合物 |
JPH06345772A (ja) | 1993-06-15 | 1994-12-20 | Tokuyama Soda Co Ltd | 新規化合物 |
JPH07285931A (ja) | 1994-04-19 | 1995-10-31 | Tokuyama Corp | 新規化合物 |
PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
TR200003719T2 (tr) * | 1998-06-19 | 2001-03-21 | Pfizer Products Inc. | Pirolo[2,3-d]Pirimidin bileşikleri |
EP1217001B1 (en) | 1999-09-28 | 2005-12-07 | Eisai Co., Ltd. | Quinuclidine compounds and drugs containing the same as the active ingredient |
DE19960917A1 (de) | 1999-12-17 | 2001-06-21 | Bayer Ag | Neue 3-Oxo-2,1-benzisoxazol-1(3H)-carboxamide zur Behandlung von ZNS-Erkrankungen |
YU83302A (sh) * | 2000-06-26 | 2005-09-19 | Pfizer Products Inc. | Jedinjenja pirolo (2,3-d) pirimidina kao imunosupresivni agensi |
GB0018951D0 (en) | 2000-08-03 | 2000-09-20 | Smithkline Beecham Plc | Novel compounds |
ZA200602666B (en) * | 2004-01-12 | 2007-09-26 | Cytopia Res Pty Ltd | Selective kinase inhibitors |
FR2881742B1 (fr) | 2005-02-10 | 2007-09-07 | Aventis Pharma Sa | Pyrroles substitues, compositions les contenant, procede de fabrication et utilisation |
US20060183758A1 (en) * | 2005-02-17 | 2006-08-17 | Cb Research And Development, Inc. | Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans |
UA93538C2 (en) * | 2006-01-23 | 2011-02-25 | Амген Инк. | Aurora kinase modulators and method of use |
JP2009534454A (ja) | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
GB0608268D0 (en) * | 2006-04-26 | 2006-06-07 | Cancer Rec Tech Ltd | Therapeutic compounds |
KR20090106604A (ko) * | 2007-01-12 | 2009-10-09 | 아스텔라스세이야쿠 가부시키가이샤 | 축합 피리딘 화합물 |
ES2563458T3 (es) * | 2007-03-23 | 2016-03-15 | Amgen Inc. | Compuestos heterocíclicos y sus usos |
EP3536687B8 (en) * | 2007-11-28 | 2021-09-08 | Dana-Farber Cancer Institute, Inc. | Small molecule myristate inhibitors of bcr-abl and methods of use |
JP5629324B2 (ja) * | 2009-10-15 | 2014-11-19 | ファイザー・インク | ピロロ[2,3−d]ピリミジン化合物 |
-
2010
- 2010-08-26 TW TW099128684A patent/TW201111385A/zh unknown
- 2010-08-27 JP JP2012527032A patent/JP2013503191A/ja not_active Withdrawn
- 2010-08-27 US US13/392,383 patent/US20120149662A1/en not_active Abandoned
- 2010-08-27 WO PCT/US2010/046999 patent/WO2011031554A2/en active Application Filing
- 2010-08-27 EP EP10748213A patent/EP2470537A2/en not_active Withdrawn
- 2010-08-27 RU RU2012111215/04A patent/RU2012111215A/ru unknown
- 2010-08-27 MX MX2012002217A patent/MX2012002217A/es unknown
- 2010-08-27 CN CN2010800478850A patent/CN102574863A/zh active Pending
- 2010-08-27 BR BR112012008073A patent/BR112012008073A2/pt not_active Application Discontinuation
- 2010-08-27 KR KR1020127007918A patent/KR20120060867A/ko not_active Application Discontinuation
- 2010-08-27 AU AU2010292487A patent/AU2010292487A1/en not_active Abandoned
- 2010-08-27 AR ARP100103144A patent/AR077990A1/es unknown
- 2010-08-27 CA CA2770712A patent/CA2770712A1/en not_active Abandoned
-
2012
- 2012-02-23 IL IL218271A patent/IL218271A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW201111385A (en) | 2011-04-01 |
AR077990A1 (es) | 2011-10-05 |
IL218271A0 (en) | 2012-04-30 |
KR20120060867A (ko) | 2012-06-12 |
WO2011031554A2 (en) | 2011-03-17 |
EP2470537A2 (en) | 2012-07-04 |
BR112012008073A2 (pt) | 2016-03-01 |
CN102574863A (zh) | 2012-07-11 |
JP2013503191A (ja) | 2013-01-31 |
US20120149662A1 (en) | 2012-06-14 |
RU2012111215A (ru) | 2013-10-10 |
CA2770712A1 (en) | 2011-03-17 |
WO2011031554A3 (en) | 2011-09-15 |
AU2010292487A1 (en) | 2012-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012002217A (es) | Compuestos heterociclicos como inhibidores de cinasa janus. | |
MX2012001420A (es) | Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus. | |
WO2011079230A3 (en) | Heterocyclic compounds as janus kinase inhibitors | |
PH12015501585A1 (en) | Manufacturing process for pyrimidine derivatives | |
MX352672B (es) | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. | |
MX362550B (es) | Inhibidores ciclicos de glutaminasa. | |
TN2013000434A1 (en) | Novel imidazole derivatives useful for the treatment of arthritis | |
HK1131608A1 (en) | Pyridinone compounds | |
NZ705253A (en) | Derivatives of azaindazole or diazaindazole type for treating pain | |
JO2998B1 (ar) | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان | |
BR112012029994A2 (pt) | composto heterocíclicos como inibidores de janus quinase | |
IN2014KN00929A (es) | ||
MX2012000709A (es) | Inhibidores de pirrolopiridina de cinasas. | |
MX340402B (es) | Inhibidores triciclicos de cinasas. | |
MA34064B1 (fr) | Compose heterocyclique | |
IN2014KN00948A (es) | ||
TN2014000058A1 (en) | A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes | |
MX2013010898A (es) | Novedoso derivados de la pirimidina. | |
MX2013012588A (es) | Inhibidores de cinasa. | |
MX2011011776A (es) | Nuevos profarmacos de triptolite. | |
MX2021006544A (es) | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. | |
WO2013109972A3 (en) | Therapeutic compounds | |
WO2014047110A3 (en) | Substituted alkyl diaryl derivatives, methods of preparation and uses | |
NZ700356A (en) | Pyrazole compounds as sglt1 inhibitors | |
MX2012006897A (es) | Compuestos heterociclicos como inhibidores de janus cinasa. |